Among these trials, the combination of R-DHAP regimen with temsirolimus, an mTOR inhibitor, has shown encouraging results, demonstrating improved outcomes in patients with r/r DLBCL (47). This evidence concerns the gene MTOR and diffuse large B-cell lymphoma.